CorticorpNews
Back to Finance
Expand

Updated

Moderna raised its 2026 revenue growth outlook to 15% to 25%, up from its previous guidance of up to 10%, CNBC reported on November 6, 2026. The company's CEO said newer vaccines are gaining traction. Moderna also filed a Form 8-K with the SEC the same morning, and the excerpts did not include further detail on the filing.

Sources:CNBC Top NewsSEC EDGAR Current 8-K Filings (all issuers)

2 outlets · 2 articles · first seen Nov 6, 7:00 AM ET

What this touches in markets

Stored closes for the instruments tied to this story's tags and places, with their dates.

  • MRNA closed at 241.46, down 6.55%, on 2026-11-05. Listed for: ticker the story is tagged with.
  • XLV closed at 184.91, down 2.50%, on 2026-11-05. Listed for: Health Care sector ETF.

Every source article